CAPR Stock Jumps As Street Hikes Price Targets Into FDA Catalyst
Capricor Therapeutics (CAPR) stock rose 13.28% after B. Riley and Piper Sandler upgraded it, setting price targets of $21 and $25 respectively, ahead of an FDA decision on its lead therapy, deramiocel, on November 22, 2026. The company reported a net loss of $40.7M and cash burn of $31M, but holds significant cash and minimal debt. Analysts' average price target is $31.78.
How this was made
The 30-second read
Why it matters
The upgrades signal a shift in market perception, likely attracting momentum traders and increasing volume.
Market read
CAPR's price action is driven by analyst upgrades ahead of a key FDA decision, creating a short‑term trading opportunity.
What to watch
High cash burn and negative earnings could limit upside if the catalyst stalls.
Background
CAPR is a development‑stage biotech with a pending FDA decision on its lead therapy deramiocel (Nov 22 2026). Recent analyst upgrades have sharply raised price targets.
Ticker impact
B. Riley and Piper Sandler upgraded CAPR to Overweight and raised price targets to $21 and $25, driving a 13.3% intraday jump.
upward pressure as short-term traders chase the upgrade, with risk of pull‑back after the initial spike.
Two independent upgrades on the same day, large target hikes, and a recent FDA decision date provide clear catalyst for further buying.
Market effects
Catalyst‑driven biotech stocks may see heightened volatility ahead of FDA decision dates.
U.S. small‑cap biotech sector gains modest attention.
Limited to investors focused on U.S. biotech catalysts.
Counterpoint
The stock may face sharp downside if FDA decision disappoints or if profit‑taking accelerates after the upgrade rally.
Key entities
- AnalystB. Riley
Upgraded CAPR to Buy, raised target to $21.
- AnalystPiper Sandler
Upgraded CAPR to Overweight, raised target to $25.
